REG - ValiRx PLC - VAL201 Clinical Trial Update <Origin Href="QuoteRef">VALX.L</Origin>

ValiRxAnnouncement

16/02/2016 07:00

RNS Number : 1390P
ValiRx PLC
16 February 2016
ValiRx Plc
("ValiRx"or "theCompany")
VAL201 CLINICAL TRIAL UPDATE
Cohort Review Committee - Final dose escalation approved.
London, UK, 16th February 2016: ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, provides a clinical trial update.
Closely following the quarterly update released on 9 February 2016, ValiRx announces that a further cohort of subjects have successfully completed the core part of their clinical trial dosing sequence with no significant adverse events being reported among the participants. In light of this, the trial's Cohort Review Committee has recommended that the final dose escalation be approved.
The trial itself continues according to its approved design and its schedule is on time. Further updates and information will be provided during the dose expansion phase, during which the specific tumour modulating effects that were shown preclinically and have been hinted at during the in-human stage, are being specifically investigated. Safety and tolerability throughout the trial will continue to be paramount.
The Company believes that being able to dose patients at levels and with a frequency that matches the pre-clinical validated amounts that are therapeutically relevant, represents another important milestone.
*** ENDS ***
For more information, please contact:
ValiRx plc
Tel: +44 (0) 20 3008 4416
Dr Satu Vainikka, Chief Executive
www.valirx.com
Tarquin Edwards, Head of Communications.
 Tel: +44 (0) 7879 458 364

tarquin.edwards@valirx.com


Cairn Financial Advisers LLP (Nominated Adviser)
Tel: +44 (0) 20 7148 7900
Liam Murray / Avi Robinson



Northland Capital Partners Limited (Broker)
Tel: +44 (0) 20 7382 1100
Patrick Claridge / David Hignell (Corporate Finance)

John Howes / Abigail Wayne (Broking)

About ValiRx Plc 
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
The Company listed onthe Alternative Investment Market ("AIM") of the London StockExchange in October 2006.
The Company has a pipeline ofother therapeutic drugs, which are currently progressing towards clinicaltrials. The product focus is in the targeted analysis and treatment of cancer,but thetechnologies can be applied to other fields as well, such as neurologyand inflammatory diseases. It actively manages projectswithin its portfolio as a trading company. The ValiRx business model spreads the risks of life science technologydevelopment by minimizing financial exposure andrunning a set of projects todefined commercial endpoints. This maximizes returns to shareholders by adding value at the earlier stages where value increases per investment unit are thegreatest.
The Company operates through the following divisional companies:
1. ValiPharma is the therapeuticsdivision, with two embedded technologies primarily directed at the treatment ofcancers.
2. ValiFinn is the biomarkers anddiagnostic development division. ValiRx acquired through its ValiFinn subsidiary, the complimentary TRAC technology to strengthen the portfolio.
3. ValiSeek is a joint venture between ValiRx and Tangent Ltd to develop Val401 in lung cancer and potentially other indications.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RESGGUGPPUPQGRA